US2016206634A1PendingUtilityA1

Omega-3 phospholipid supplements for improved brain maturity

Assignee: AKER BIOMARINE ANTARCTIC ASPriority: Mar 14, 2013Filed: Mar 28, 2016Published: Jul 21, 2016
Est. expiryMar 14, 2033(~6.6 yrs left)· nominal 20-yr term from priority
A61K 31/122A61K 9/0053A23J 7/00A61K 31/23A61K 31/661A23L 33/115A23L 33/00A61K 31/194A23V 2002/00A23L 33/10
43
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention relates to omega-3 phospholipid supplements for use in adolescents, and in particular to use omega-3 phospholipid supplements to improve or support brain maturity age. In preferred embodiments, the omega-3 phospholipid is krill oil.

Claims

exact text as granted — not AI-modified
1 . A method of improving or supporting brain maturity age in a subject in need thereof comprising:
 administering an omega-3 phospholipid supplement to said subject under conditions such that the brain maturity age of the subject is improved.   
     
     
         2 . The method of  claim 1 , wherein said omega-3 phospholipid supplement is a krill oil, fish oil, fish roe oil, or fish byproduct oil. 
     
     
         3 . The method of  claim 2 , wherein said krill oil comprises from about 35% to 60% phospholipids on a w/w basis; from about 20% to 45% triglycerides on a w/w basis; and from about 50 to about 2500 mg/kg astaxanthin. 
     
     
         4 . The method of  claim 3 , wherein said krill oil comprises from about 3% to 10% ether phospholipids on a w/w basis, so that the total amount of ether phospholipids and non-ether phospholipids in the composition is from about 48% to 60% on a w/w basis. 
     
     
         5 . The method of  claim 4 , wherein said krill oil comprises from about 25% to 30% omega-3 fatty acids as a percentage of total fatty acids and wherein from about 80% to 90% of said omega-3 fatty acids are attached to said phospholipids. 
     
     
         6 . The method of  claim 5 , wherein said krill oil comprises from about 100 to about 2500 mg/kg astaxanthin. 
     
     
         7 . The method of  claim 1 , wherein said omega-3 supplement comprises from about 1% to about 10% w/w ether phospholipids; from about 27% to 50% w/w non-ether phospholipids so that the amount of total phospholipids in the composition is from about 30% to 60% w/w; from about 20% to 50% w/w triglycerides; from about 100 to about 2500 mg/kg astaxanthin; and from about 20% to 35% omega-3 fatty acids as a percentage of total fatty acids in said composition, wherein from about 70% to 95% of said omega-3 fatty acids are attached to said phospholipids. 
     
     
         8 . The method of  claim 1 , wherein said omega-3 is selected from EPA and DHA and combinations thereof. 
     
     
         9 . The method of  claim 1 , wherein said subject is an adolescent. 
     
     
         10 . The method of  claim 9 , wherein said adolescent is a male. 
     
     
         11 . The method of  claim 1 , wherein said administration is oral. 
     
     
         12 . The method of  claim 1 , wherein said omega-3 phospholipid supplemented is administered a daily dosage of from about 3 grams to about 6 grams per day. 
     
     
         13 . The method of  claim 12 , wherein said daily dose is administered in two doses of from 1.5 to 3 grams in the morning and evening. 
     
     
         14 . The method of  claim 1 , wherein said subject has been diagnosed with ADHD. 
     
     
         15 . The method of  claim 1 , wherein said brain maturation age is calculated by comparison of EEG measurements with reference EEG measurements. 
     
     
         16 . A method of improving or supporting brain maturity age in a subject in need thereof comprising:
 administering a krill oil supplement to said subject under conditions such that the brain maturity age of the subject is improved, wherein said krill oil supplement comprises from about 35% to 60% phospholipids on a w/w basis, from about 20% to 45% triglycerides on a w/w basis, and from about 50 to about 2500 mg/kg astaxanthin, and wherein said brain maturation age is calculated by comparison of EEG measurements with reference EEG measurements.   
     
     
         17 . The method of  claim 16 , wherein said subject is an adolescent male. 
     
     
         18 . The method of  claim 16 , wherein said administration is oral. 
     
     
         19 . The method of  claim 16 , wherein said omega-3 phospholipid supplemented is administered a daily dosage of from about 3 grams to about 6 grams per day. 
     
     
         20 . The method of  claim 19 , wherein said daily dose is administered in two doses of from 1.5 to 3 grams in the morning and evening.

Join the waitlist — get patent alerts

Track US2016206634A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.